Marker Therapeutics 10-Q: Equity Offering & Financial Update
Ticker: MRKR · Form: 10-Q · Filed: May 15, 2025 · CIK: 1094038
| Field | Detail |
|---|---|
| Company | Marker Therapeutics, Inc. (MRKR) |
| Form Type | 10-Q |
| Filed Date | May 15, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financing, equity-offering, pharmaceutical
TL;DR
Marker Therapeutics 10-Q filed. Equity offering with Cantor/RBC ongoing. Financials updated.
AI Summary
Marker Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as TAPIMMUNE INC., reported on its financial status, including changes in Additional Paid-In Capital and Retained Earnings. The filing also references a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. and RBC Capital Markets, LLC.
Why It Matters
This filing provides investors with an update on Marker Therapeutics' financial health and ongoing financing activities, which are crucial for its operations and future development.
Risk Assessment
Risk Level: medium — The company's reliance on equity offerings and its financial performance in a competitive pharmaceutical sector present inherent risks.
Key Numbers
- 20250331 — Reporting Period End (The 10-Q covers the financial period ending March 31, 2025.)
- 20250515 — Filing Date (The report was officially filed on May 15, 2025.)
Key Players & Entities
- Marker Therapeutics, Inc. (company) — Filer
- TAPIMMUNE INC. (company) — Former company name
- Cantor Fitzgerald & Co. (company) — Underwriter in equity offering
- RBC Capital Markets, LLC (company) — Underwriter in equity offering
- 20250331 (date) — Reporting period end date
FAQ
What was Marker Therapeutics' financial performance during the quarter ending March 31, 2025?
The 10-Q filing for the period ending March 31, 2025, details changes in the company's financial position, including Additional Paid-In Capital and Retained Earnings, but specific profit/loss figures are not detailed in the provided header information.
What is the nature of the agreement with Cantor Fitzgerald & Co. and RBC Capital Markets, LLC?
The filing references a 'Controlled Equity Offering Sales Agreement' with Cantor Fitzgerald & Co. and RBC Capital Markets, LLC, indicating these firms are involved in the company's equity sales.
When did Marker Therapeutics change its name from TAPIMMUNE INC.?
Marker Therapeutics, Inc. changed its name from TAPIMMUNE INC. on June 29, 2017.
What is Marker Therapeutics' primary business sector?
Marker Therapeutics, Inc. operates in the Pharmaceutical Preparations sector, with SIC code 2834.
What is the company's fiscal year end?
Marker Therapeutics, Inc.'s fiscal year ends on December 31.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 15, 2025 regarding Marker Therapeutics, Inc. (MRKR).